Stock Analysis
- Japan
- /
- Personal Products
- /
- TSE:4917
Here's What Analysts Are Forecasting For Mandom Corporation (TSE:4917) After Its Third-Quarter Results
Investors in Mandom Corporation (TSE:4917) had a good week, as its shares rose 4.0% to close at JP¥1,248 following the release of its third-quarter results. Mandom reported in line with analyst predictions, delivering revenues of JP¥18b and statutory earnings per share of JP¥57.84, suggesting the business is executing well and in line with its plan. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Mandom after the latest results.
See our latest analysis for Mandom
Taking into account the latest results, the most recent consensus for Mandom from five analysts is for revenues of JP¥79.9b in 2026. If met, it would imply a credible 5.6% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to leap 29% to JP¥64.82. Yet prior to the latest earnings, the analysts had been anticipated revenues of JP¥80.0b and earnings per share (EPS) of JP¥62.32 in 2026. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates.
There's been no major changes to the consensus price target of JP¥1,284, suggesting that the improved earnings per share outlook is not enough to have a long-term positive impact on the stock's valuation. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. There are some variant perceptions on Mandom, with the most bullish analyst valuing it at JP¥1,320 and the most bearish at JP¥1,200 per share. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.
Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Mandom's rate of growth is expected to accelerate meaningfully, with the forecast 4.5% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 0.2% p.a. over the past five years. Other similar companies in the industry (with analyst coverage) are also forecast to grow their revenue at 4.0% per year. Mandom is expected to grow at about the same rate as its industry, so it's not clear that we can draw any conclusions from its growth relative to competitors.
The Bottom Line
The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Mandom following these results. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Mandom analysts - going out to 2027, and you can see them free on our platform here.
Plus, you should also learn about the 1 warning sign we've spotted with Mandom .
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:4917
Mandom
Engages in the manufacture and sale of cosmetics, perfumes, and quasi-drugs in Japan, Indonesia, and internationally.